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Lower Nicotine Cigarettes may not Lower Harm
Abstract
In 2005, nearly 21% of American adults smoked cigarettes, and 81% of them smoked every day. For
smokers unable or unwilling to quit, tobacco products that reduce the adverse health effects of smoking
may be an attractive option. Potentially reduced exposure products (PREPs) were developed by the
tobacco industry in response to smokers’ health concerns. PREPs purportedly lower the tar and/or
nicotine levels of cigarettes, although the actual harm reduced remains questionable. One of the most
recent additions to this product class are cigarettes that use genetically modified tobacco to reduce
nicotine levels. This Issue Brief summarizes studies that investigate [1] how this product is used and [2]
the messages smokers take away from product marketing. These complementary studies send a
cautionary signal about the ability of these new cigarettes to reduce the harmful effects of smoking.
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Lower Nicotine Cigarettes May Not Lower Harm

About Quest® and other
potential harm-reducing
products

Currently marketed in eight states, Quest® cigarettes are one of the most recent entries
in the class of products designed to reduce exposure to toxic substances in tobacco.
However, whether such products actually reduce harm depends on how smokers use the
product.

Editor’s note: In 2005, nearly 21% of American adults smoked cigarettes, and 81%
of them smoked every day. For smokers unable or unwilling to quit, tobacco
products that reduce the adverse health effects of smoking may be an attractive
option. Potentially reduced exposure products (PREPs) were developed by the
tobacco industry in response to smokers’ health concerns. PREPs purportedly lower
the tar and/or nicotine levels of cigarettes, although the actual harm reduced remains
questionable. One of the most recent additions to this product class are cigarettes
that use genetically modified tobacco to reduce nicotine levels. This Issue Brief
summarizes studies that investigate [1] how this product is used and [2] the messages
smokers take away from product marketing. These complementary studies send a
cautionary signal about the ability of these new cigarettes to reduce the harmful
effects of smoking.

• Quest® uses genetically modified tobacco to reduce nicotine levels. The cigarettes are
manufactured with three progressively lower nicotine levels (0.6, 0.3, and 0.05 mg)
and marketed as allowing smokers to “step down” to nicotine-free smoking. Each of
the three levels deliver equivalent levels of tar during standardized tests, and thus, still
pose health risks.
• Previous studies demonstrate that smokers may change their smoking behavior when
switching to “light” cigarettes, by taking larger or more frequent puffs. The lower
nicotine cigarettes in these studies had design features that allowed smokers to extract
more nicotine by increasing puffing or occluding filter ventilation holes.
• Such “compensatory” behavior may mean that smokers are exposed to as much, if not
more, harmful substances than regular cigarettes. Whether smokers alter their
smoking behavior with Quest® cigarettes is unknown.
• Quest® cigarettes are not marketed for use as a smoking cessation device, nor are any
health claims explicitly made in the product’s advertising. As such, Quest® advertising
is not regulated by the Food and Drug Administration (FDA). Instead, the content
of ads falls under the purview of the Federal Trade Commission (FTC), whose
primary goal is to ensure that products are marketed in a manner than is truthful, not
misleading, and adequately substantiated.
Continued on next page.

Laboratory study measures
puff volume and carbon
monoxide after smoking
Quest® cigarettes

Strasser and colleagues conducted a laboratory study to evaluate whether compensatory
smoking occurs as nicotine levels in Quest® cigarettes decrease. How a cigarette is
smoked is referred to as “smoking topography” and includes measures such as number of
puffs, puff volume, duration, and velocity.
• Smokers of “light” cigarettes can increase their nicotine levels by changing their
smoking topography. In contrast, smokers who use Quest® may not be able to
increase their nicotine levels through compensation, especially when the genetically
modified tobacco contains virtually no nicotine. However, most smokers are unlikely
to be fully aware of this feature, and thus may continue compensatory smoking.
• The researchers investigated the effects of using Quest® cigarettes on smoking
topography and carbon monoxide exposure. Fifty adult smokers participated in the
study, in which they smoked Quest® cigarettes using a machine that measures
smoking behavior. Cigarettes are placed in a sterilized mouthpiece attached to an airfilled tube which leads to a pressure transducer.
• Participants first smoked their own brand to allow them to become accustomed to the
smoking topography device. Thirty minutes later, they smoked each of three levels of
Quest® cigarettes, thirty minutes apart. Participants completed a questionnaire that
asked them to rate the cigarette they had just finished. None of the participants had
previously used the product, and both study staff and participants were unaware of
the nicotine level of each cigarette.
• The researchers measured total puff volume after each cigarette, as an indicator of
changes in smoking behavior. They measured carbon monoxide from breath samples
taken before and after each cigarette. The difference between pre- and post-cigarette
carbon monoxide is considered the carbon monoxide “boost,” and is a biochemical
indicator of exposure to smoke.

• Total puff volume increased as nicotine levels in Quest® cigarettes decreased. Puff
volume when smoking the 0.05 mg nicotine cigarette was significantly greater than
when smoking the 0.3 mg nicotine cigarette, and moderately greater than the 0.6 mg
nicotine cigarette.
• Carbon monoxide boost was significantly greater after smoking the 0.05 mg and 0.3
mg cigarettes compared to the 0.6 mg nicotine cigarette.

CO boost (ppm)

Total Puff Volume (ml)

Lower nicotine cigarettes
can produce compensatory
smoking and increased
carbon monoxide exposure

•

Overall, these effects on puff volume and carbon monoxide were
statistically significant, although may appear modest due to some
smokers compensating while others did not.

•

1 of 5 participants had a 20% or greater increase in total puff
volume when smoking the lowest nicotine cigarette compared to
when smoking the highest nicotine cigarette. The majority of
participants had small increases when cigarette nicotine levels
decreased; only 3 participants exhibited larger total puff volume
when smoking the higher nicotine cigarette.

•

Further, 2 of 5 participants had a 20% or greater increase in
carbon monoxide boost when smoking the lowest nicotine
cigarette compared to when smoking the highest nicotine
cigarette. For those who did compensate by significantly
increasing their total puff volume, carbon monoxide boost
increased about 300%, on average.

•

At the conclusion of the study, participants were asked to identify
the Quest® cigarettes with the least and most nicotine. Fifty-four

Quest cigarette nicotine level (mg)

The effect of cigarette nicotine level on total
puff volume (solid bars); and average carbon
monoxide boost (open bars).

percent correctly identified the 0.6 mg nicotine cigarette as the highest, 58%
identified the 0.05 mg as the lowest, and 38% correctly identified both the highest
and lowest. The ability to identify these cigarettes did not affect total puff volume or
carbon monoxide boost, but those who correctly discriminated cigarette nicotine level
rated the 0.6 mg nicotine cigarette as strongest and most satisfying and the 0.05 mg
nicotine cigarette as least strong and satisfying.

Study assesses smokers’
initial responses to Quest®
advertising

Outside of the controlled environment of a laboratory study, smoking behavior can be
affected by how smokers perceive the new low-nicotine cigarettes. The researchers
evaluated how regular smokers initially respond to a print ad for Quest® cigarettes.
• The study included 200 smokers recruited in
shopping malls in 14 states (in which Quest®
cigarettes are not marketed). Only 8% of
participants had ever heard of Quest®
cigarettes prior to the study, and none had
tried them.
• The participants viewed a single Quest®
print ad for 30 seconds, which is longer than
most consumers spend on ads in general.
The ad (shown here in small scale) describes
three levels of reduced nicotine, indicates
that tar levels are not reduced, and explicitly
states that Quest® cigarettes are not intended
to assist smokers with quitting.
• After seeing the ad, the participants answered
a series of questions about the nicotine and
tar content of the new cigarettes and the
healthiness and safety relative to other cigarettes.
• The researchers also assessed two individual traits previously shown to influence how
people respond to persuasive communication: the individual’s motivation to process
the information (defined in this case as perceived vulnerability to the health effects of
smoking), and the need for cognition (defined as the degree to which the individual
enjoys thinking about complex issues).

After reading an
advertisement, many
smokers incorrectly believe
that Quest® cigarettes are
healthier and lower in tar
than other cigarettes

Despite a lengthy 30-second reading time, many smokers made false inferences about tar
levels of Quest® cigarettes—the material that contains cancer-causing chemicals.
• About 60% of participants correctly answered that Quest® cigarettes are lower in
nicotine. About 45% of participants inferred incorrectly that Quest® cigarettes are
lower in tar.
• Participants scoring lower on perceived vulnerability and need for cognition made
more false inferences about the nicotine levels in Quest® cigarettes compared with all
other groups.
• Participants scoring higher on perceived vulnerability and need for cognition were
more likely to infer correctly that Quest® cigarettes were no healthier than regular
cigarettes.
• These findings suggest that smokers who are less motivated to think about the health
effects of smoking, and who tend not to enjoy thinking critically in general, are
vulnerable to misperceptions about the health and safety of Quest® cigarettes.
Continued on back.

POLICY IMPLICATIONS

These findings raise concern in two related areas. First, they provide behavioral and
biochemical evidence for the possibility of compensatory smoking with a new low
nicotine product, supporting the potential for increased, rather than reduced, harm.
Second, they suggest that many smokers make false inferences about the relative safety of
these cigarettes based on the product’s advertisement.
• If a new cigarette is misperceived as less harmful, it may attract smokers who would
otherwise have quit or reduced smoking. Further research is needed to assess how
Quest® cigarettes may divert smokers from more effective ways to reduce their harm
from tobacco, including trying to quit smoking.
• The FTC’s legal framework for deceptive advertising considers whether the
advertising conveys a message that is likely to mislead reasonable consumers to their
detriment. The marketing study suggests that the Quest® advertising may mislead the
public.
• These results reinforce that public health awareness campaigns should strive to
increase the perception that any smoking, even smoking low nicotine cigarettes, can
have serious health effects—regardless of nicotine content.

This Issue Brief is based on the following articles: A.A. Strasser, C. Lerman, P.M. Sanborn, W.B. Pickworth, and E.A. Feldman. New lower
nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. Drug and Alcohol Dependence, 2007, vol. 86, pp.
294-300; W.G. Shadel, C. Lerman, J. Cappella, A.A. Strasser, A. Pinto, R. Hornik. Evaluating smokers’ reactions to advertising for new lower
nicotine Quest® cigarettes. Psychology of Addictive Behaviors, March 2006, vol. 20, pp.80-84.
This Issue Brief was supported by National Cancer Institute grant P50CA101404 and P50CA/DA84718.
Published by the Leonard Davis Institute of Health Economics, University of Pennsylvania, 3641 Locust Walk, Philadelphia, PA 19104-6218.
Janet Weiner, MPH, Associate Director for Health Policy, Editor (215-573-9374)
Visit us on the web at www.upenn.edu/ldi
David A. Asch, MD, MBA, Executive Director
Issue Briefs synthesize the results of research by LDI’s Senior Fellows, a consortium of Penn scholars studying medical, economic, and social and ethical
issues that influence how health care is organized, financed, managed, and delivered in the United States and internationally. The LDI is a cooperative
venture among Penn schools including Dental Medicine, Medicine, Nursing and Wharton, and the Children’s Hospital of Philadelphia. For additional
information on this or other Issue Briefs, contact Janet Weiner (e-mail: weinerja@mail.med.upenn.edu; 215-573-9374).
© 2006 Leonard Davis Institute

Published by the
Leonard Davis Institute
of Health Economics
University of Pennsylvania

Issue Brief
ADDRESS CORRECTION REQUESTED

3641 Locust Walk
Philadelphia, PA 19104-6218
215.898.5611
fax 215.898.0229

P A I D
Permit No. 2563
Philadelphia, PA 19104
Nonprofit Organization
U.S. Postage

